Cantor Fitzgerald initiated research coverage of ProMIS Neurosciences (PMN) with an Overweight rating. The clinical-stage biotechnology firm develops antibody therapeutics for neurodegenerative diseases including Alzheimer's and ALS.
Wall Street analysts maintain a consensus buy rating on the company. Current price targets suggest significant upside potential from present trading levels.
ProMIS is currently conducting the PRECISE-AD Phase 1b clinical trial for its lead Alzheimer's candidate, PMN310. The company expects to release key data from this study in the near future.